

US Non-Invasive Prenatal Diagnostics - Market Insight

<https://marketpublishers.com/r/U5A692FF709EN.html>

Date: May 2013

Pages: 60

Price: US\$ 1,200.00 (Single User License)

ID: U5A692FF709EN

Abstracts

The US prenatal diagnostics market is one of the largest markets in the world for foetal monitoring, diagnostics, and predictive testing. It consists of a series of physician prescribed tests for monitoring maternal and foetal health. The current invasive technologies such as CVS and amniocentesis that are used to detect chromosomal abnormalities pose serious risks of miscarriages and are being replaced by the non-invasive prenatal diagnostics technologies.

Although NIPD is a relatively nascent segment of the prenatal diagnostics, it presents a lucrative growth potential to industry participants. The segment is mainly supported by rising incidences of foetal health-related abnormalities and the urgent need for safe, accurate and early diagnosis. Products such as MaterniT21 Plus, Verifi, and Harmony prenatal tests are the current tests available in the market. Around 100,000 samples were likely tested by MaterniT21 plus test alone by the first quarter of 2013 since its launch.

Further the report “US Non-Invasive Prenatal Diagnostics - Market Insight”, provides a transparent view on the present regulatory framework elaborating on the existing loopholes. A thorough analysis has been done illustrating the views of regulatory authorities, players and consumers towards the regulatory stringency, and the direction of regulations in the future have also been covered.

Currently, the US NIPD sector is characterized by the presence of players like Sequenom, Verinata, Ariosa and Natera. These companies are effectively taking steps to promote their LDTs among the US population especially targeting physicians to recommend their products. In future, the launch of Natera’s test is expected to impact the market significantly, thereby boosting the potential size and sample volume.

The report, which provides a prudent analysis on the current and future size of the

market weighing the possible pessimistic and optimistic scenarios, is a must buy for new market entrants in the diagnostics field, planning to enter the prenatal segment.

Contents

1. ANALYST VIEW

2. RESEARCH METHODOLOGY

3. STATISTICAL SNAPSHOT - PREGNANCIES AND CHROMOSOMAL ABNORMALITIES

4. OVERVIEW OF US PRENATAL DIAGNOSTICS MARKET

4.1 Introduction

4.2 Prenatal Diagnostics Industry

4.2.1 Preliminary Prenatal Testing

4.2.2 First Trimester Screening

4.2.3 Second Trimester Screening

4.2.4 Chorionic Villus Sampling (CVS) Testing

4.2.5 Amniocentesis Testing

5. US NON-INVASIVE PRENATAL DIAGNOSTICS - MARKET INSIGHT

5.1 Tests Available in the Market

5.1.1 MaterniT21 (Sequenom)

5.1.2 Verifi (Verinata Health)

5.1.3 Harmony Prenatal Test (Ariosa Diagnostics)

5.1.4 Panorama (Natera)

5.2 Current and Future Market Projections to 2017

5.3 Regulatory Insight

5.3.1 Current Regulatory Scenario

5.3.2 Regulatory Authority Perspective

5.3.3 Diagnostic Test Provider Perspective

5.3.4 Consumers' Perspective

5.3.5 Analyst Inputs

6. CURRENT TECHNOLOGIES IN THE MARKET

7. CONSTRAINTS IN NIPD MARKET

8. COMPETITIVE ASSESSMENT

8.1 Ariosa Diagnostics

8.1.1 Company Overview

8.1.2 Product Overview

8.1.3 Strengths and Weaknesses

8.2 Sequenom

8.2.1 Company Overview

8.2.2 Product Overview

8.2.3 Strengths and Weaknesses

8.3 Verinata

8.3.1 Company Overview

8.3.2 Product Overview

8.3.3 Strengths and Weaknesses

8.4 Natera

8.4.1 Company Overview

8.4.2 Product Overview

8.4.3 Strengths and Weaknesses

List Of Figures

LIST OF FIGURES

- Figure 3-1: Population Base (Million), 2000-2010
- Figure 4-1: Prenatal Testing Market (Billion US\$), 2012-2016
- Figure 4-2: Preliminary Prenatal Testing Market (Million US\$), 2012-2016
- Figure 4-3: First Trimester Screening Market (Million US\$), 2012-2016
- Figure 4-4: Second Trimester Screening Market (Million US\$), 2012-2016
- Figure 4-5: CVS Testing Market (Million US\$), 2012-2016
- Figure 4-6: Amniocentesis Testing Market (Million US\$), 2012-2016
- Figure 5-1: Non-Invasive Prenatal Diagnostics Market (Million US\$), 2012-2017
- Figure 5-2: Share of Players in Number of NIPD Tests Performed (2012)
- Figure 5-3: Share of Players in NIPD Market (2012)
- Figure 5-4: Forecast for Share of Players in Number of NIPD Tests Performed (2017)
- Figure 5-5: Forecast for Share of Players in NIPD Market (2017)
- Figure 5-6: Laboratorians' Attitudes towards FDA's Regulations on Lab Developed Tests (LDT)

List Of Tables

LIST OF TABLES

Table 3-1: Number of Births and Abortions (2000-2010)

Table 3-2: Number of Multiple Pregnancies (2000-2009)

Table 3-3: Prevalence of Chromosomal Abnormalities

Table 4-1: Major Preliminary Prenatal Tests Performed

Table 4-2: Major First Trimester Screening Tests Performed

Table 4-3: Major Second Trimester Screening Tests Performed

Table 5-1: Inter-comparison of CLIA and FDA Regulatory Pathway

Table 6-1: Common Commercial Kits and Protocols for Isolation of ccff DNA from Maternal Plasma

I would like to order

Product name: US Non-Invasive Prenatal Diagnostics - Market Insight

Product link: <https://marketpublishers.com/r/U5A692FF709EN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U5A692FF709EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970